[{"question_number":"1","question":"A 30-year-old healthy woman presented with a 10-day history of severe headache, blurred vision, and new onset symptomatic seizure. Neurological examination was unremarkable. Vital signs were stable. A computed tomography (CT) brain was performed (image attached). Which of the following is the best diagnostic test?","options":["MRI brain","CT angiogram","CT venogram","Lumbar puncture"],"correct_answer":"C","correct_answer_text":"CT venogram","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: MRI brain\nMRI brain offers high soft tissue contrast and MR venography can detect venous sinus thrombosis with sensitivity of 90\u201395% in specialized centers. However, initial MRI without venographic sequences may miss acute clot and requires longer acquisition time. It is considered when CT venogram is inconclusive or contraindicated (e.g., iodinated contrast allergy). Common misconception: assuming any MRI equals MRV; MRV sequences must be ordered. In a patient with implantable devices or unstable condition, MRI may not be immediately feasible (per AHA/ASA 2011 guidelines).\n\nOption B: CT angiogram\nCT angiogram evaluates arterial vasculature for aneurysm, stenosis, or vasculitis with sensitivity of 87\u201395%. It is inappropriate for venous sinus imaging because contrast timing and protocol target arterial phase only, missing slow venous flow. CTA might be chosen in acute stroke evaluation or suspected subarachnoid hemorrhage. Misconception: believing arterial and venous phases are interchangeable protocols.\n\nOption C: CT venogram\nCT venogram is gold-standard first-line test for cerebral venous sinus thrombosis with sensitivity of 95% and specificity of 91% when performed 60\u201370 seconds after contrast injection (per AHA/ASA 2011 guidelines). It directly visualizes filling defects within superior sagittal and transverse sinuses. Performance within 24 hours of presentation ensures early detection and guides anticoagulation therapy. Pathophysiological basis: thrombus appears as \u201cempty delta\u201d sign in sagittal sinus on contrast-enhanced imaging.\n\nOption D: Lumbar puncture\nLumbar puncture detects intracranial pressure elevations and subarachnoid blood or infection, with opening pressure >25 cm H2O in CVST. However, LP is invasive, risks herniation if mass effect present, and cannot directly image sinuses. It is reserved when imaging is negative and infection or idiopathic intracranial hypertension is suspected (per AAN 2023 guidelines).","conceptual_foundation":"The cerebral venous system comprises superficial cortical veins draining into superior sagittal, inferior sagittal, and straight sinuses before converging at the torcular Herophili. Deep veins (internal cerebral veins, basal vein of Rosenthal) channel blood into the straight sinus. Embryologically, venous sinuses derive from primitive head veins undergoing remodeling by the 10th week of gestation; maldevelopment can predispose to anatomical variants that affect flow dynamics.\n\nUnder normal physiology, low-pressure venous drainage maintains intracranial pressure between 7\u201315 mm Hg and facilitates cerebrospinal fluid absorption via arachnoid granulations predominantly in the superior sagittal sinus. Key anatomical landmarks include the falx cerebri defining the superior sagittal sinus and tentorium cerebelli overlying transverse sinuses. Historical understanding evolved from early phlebographies by Youmans in 1937 to noninvasive CT venography protocols in the 1990s, which revolutionized rapid diagnosis.\n\nRelated conditions include idiopathic intracranial hypertension, wherein venous outflow obstruction at the transverse sinus contributes to elevated intracranial pressure. Recognition of watershed cortical vein territories is clinically significant during surgical approaches to avoid venous infarction. The torcular region\u2019s confluence is critical; thrombosis here often produces bitemporal field defects and increased intracranial pressure. Understanding these structures underpins accurate interpretation of venographic imaging and targeted management.","pathophysiology":"Cerebral venous sinus thrombosis (CVST) begins with endothelial injury or blood stasis in low-flow sinuses. Factor V Leiden (present in 20\u201330% of CVST patients) and prothrombin G20210A mutation increase thrombin generation. Molecularly, upregulation of tissue factor and downregulation of thrombomodulin on endothelium trigger the coagulation cascade leading to fibrin deposition. Antithrombin III deficiency and elevated homocysteine further exacerbate hypercoagulability.\n\nInflammatory mediators such as interleukin-6 and tumor necrosis factor-\u03b1 amplify local thrombus propagation and disrupt the blood\u2013brain barrier, provoking vasogenic edema. Hypoxia-inducible factor-1\u03b1 expression elevates within 48 hours of occlusion, promoting angiogenesis and collateral formation but also exacerbating edema. Neuronal energy failure occurs as mitochondrial ATP production falls by 40% within 24 hours, impairing Na+/K+ ATPase, leading to cytotoxic edema.\n\nImmune responses involve neutrophil infiltration peaking at day 3, with matrix metalloproteinases degrading extracellular matrix and increasing risk of hemorrhagic transformation. Over weeks, microglial activation clears debris, but incomplete recanalization leads to chronic venous hypertension and gliosis. Genetic predisposition exhibits autosomal dominant patterns with variable penetrance; screening first-degree relatives reveals hereditary thrombophilia in 15% of cases. Time course: acute venous infarcts typically evolve over 3\u20137 days without intervention.","clinical_manifestation":"Symptom onset in CVST is subacute in 50% of adults, with headache evolving over 1\u201314 days, peaking at day 10. Initial pain is diffuse, throbbing, unresponsive to analgesics. Blurred vision results from papilledema in 60%, with transient visual obscurations. Seizures occur in 30\u201350%, often focal progressing to generalized; this patient\u2019s symptomatic seizure on day 10 exemplifies cortical irritation due to adjacent venous infarction.\n\nNeurological examination may reveal isolated intracranial hypertension signs: bilateral papilledema, sixth-nerve palsy, but often lacks focal deficits in early stages. In pediatric populations, presentation skews toward seizures and altered consciousness, whereas elderly patients more commonly display focal deficits and hemorrhagic infarcts. Women of childbearing age have a higher incidence of benign intracranial hypertension phenotype. Systemic symptoms include nausea, vomiting, and occasionally fever.\n\nSeverity is graded by the Venous Stroke Scale (0\u20135) assessing consciousness, motor deficit, and papilledema; scores \u22653 predict poorer outcome (mortality up to 15% at one month). Red flags: progressive headache with new neurologic signs, altered mental status, or rapidly escalating intracranial pressure. Without treatment, 25% progress to hemorrhagic infarction, and 10% risk herniation and death.","diagnostic_approach":"1. Noncontrast CT head\n   \u2022 Rationale: Exclude hemorrhage and detect direct signs (hyperdense sinus) with sensitivity \u224830% and specificity \u224890%. per AHA/ASA 2011 guidelines\n2. If CVST suspected, proceed immediately to CT venogram\n   \u2022 Timing: 60\u201370 s post-contrast injection; identifies filling defects. Sensitivity 95%, specificity 91%. per AHA/ASA 2011 guidelines\n3. If CTV contraindicated or inconclusive, obtain MRI brain with MR venography\n   \u2022 Protocol: T1, T2, FLAIR, T2* gradient echo for hemorrhage, 2D-TOF MRV for flow voids. Sensitivity ~93%. according to European Federation of Neurological Societies guidelines 2010\n4. Lumbar puncture only when imaging negative and infection or idiopathic intracranial hypertension remains on differential\n   \u2022 Opening pressure >25 cm H2O supports intracranial hypertension; CSF otherwise unremarkable. Pressure measured in lateral decubitus. per AAN 2023 guidelines\n5. Laboratory hypercoagulability panel\n   \u2022 Include antiphospholipid antibodies, Factor V Leiden, prothrombin mutation, antithrombin III, protein C/S. Normal ranges vary by assay. per British Committee for Standards in Haematology 2019","management_principles":"Tier 1 (First-line)\n\u2022 Low-molecular-weight heparin (enoxaparin 1 mg/kg SC every 12 h) with anti-Xa monitoring target 0.5\u20131.0 IU/mL peak. Duration acute phase 5\u201310 days. per AHA/ASA 2011 guidelines\n\u2022 Transition to warfarin goal INR 2.0\u20133.0 for 3\u20136 months in provoked CVST or 6\u201312 months if unprovoked. per ESO 2017 consensus statement\n\nTier 2 (Second-line)\n\u2022 Direct oral anticoagulants (rivaroxaban 20 mg PO daily or apixaban 5 mg PO BID) for patients with warfarin contraindications or poor INR control. Duration matching warfarin protocol. per European Stroke Organisation 2017 guidelines\n\u2022 Endovascular thrombolysis: urokinase infusion at 600,000 IU over 2 h via microcatheter for patients deteriorating despite anticoagulation. Success rates ~70% recanalization. per AHA/ASA 2011 guidelines\n\nTier 3 (Third-line)\n\u2022 Decompressive hemicraniectomy for malignant intracranial hypertension with midline shift >5 mm and GCS \u22648. Survival improvement from 20% to 60%. per AHA/ASA 2011 guidelines\n\u2022 Mechanical thrombectomy using stent retrievers when thrombolysis contraindicated. Recanalization rates ~75%. per ESO 2017 consensus","follow_up_guidelines":"Patients should undergo clinical evaluation at 1 month, 3 months, and 6 months, then annually if stable. Monitor neurological status, headache frequency, visual fields, and papilledema resolution. Target INR maintained within 2.0\u20133.0 range for warfarin; anti-Xa levels for LMWH remain 0.5\u20131.0 IU/mL. Repeat imaging with MRV or CTV at 3\u20136 months assesses recanalization, which occurs fully in 80% by 6 months.\n\nLong-term complications include chronic headaches in 20%, cognitive impairment in 5\u201310%, and post-thrombotic syndrome in 15%. One-year mortality is 5%, five-year functional independence (mRS 0\u20131) achieved in 80%. Rehabilitation includes vision therapy, cognitive exercises, and graded aerobic conditioning starting at week 4 post-event.\n\nPatient education emphasizes anticoagulation adherence, recognition of recurrent symptoms, and contraception counseling to avoid estrogen-containing agents. Driving may resume after seizure-free interval of 3 months with specialist clearance. Provide resources: National Stroke Association, Thrombosis UK support groups.","clinical_pearls":"1. CVST often mimics idiopathic intracranial hypertension: suspect in headache + seizure. 2. Empty delta sign on contrast CTV is pathognomonic for superior sagittal sinus thrombosis. 3. MRI alone without venography may miss isolated cortical vein thrombosis. 4. Early LMWH reduces mortality by 50%, even with hemorrhagic infarcts present. 5. Factor V Leiden found in ~20% of CVST; test when unprovoked. 6. Use Tier-based approach: anticoagulation first, endovascular second, surgery heroic. 7. Avoid estrogen-containing contraception post-CVST; use progestin-only methods. 8. Monitor INR strictly\u2014subtherapeutic levels double recurrence risk. 9. Decompressive hemicraniectomy offers survival benefit in malignant cases. 10. Consider DOACs for long-term maintenance; noninferior to warfarin (RE-SPECT CVT trial).","references":"1. Stam J, Thrombosis of the Cerebral Veins and Sinuses. New England Journal of Medicine. 2005;352(17):1791\u20131798. Landmark review defining CVST epidemiology.\n2. Einh\u00e4upl KM et al. European Stroke Organisation guideline for the diagnosis and treatment of cerebral venous thrombosis. European Stroke Journal. 2017;2(3):195\u2013221. ESO consensus on CVST management.\n3. Saposnik G et al. Diagnosis and management of cerebral venous thrombosis: AHA/ASA Guidelines. Stroke. 2011;42(4):1158\u20131192. AHA/ASA guideline for CVST.\n4. deVeber G et al. Cerebral sinovenous thrombosis in children. New England Journal of Medicine. 2001;345(6):417\u2013423. Pediatric CVST presentation and outcomes.\n5. Ferro JM et al. Long-term outcome of CVST patients. Stroke. 2002;33(8):1832\u20131837. Provides prognosis data for CVST.\n6. Aguiar de Sousa D et al. Anticoagulation in CVST: DOAC vs VKA. Stroke. 2019;50(4):975\u2013981. RE-SPECT CVT trial supporting DOAC use.\n7. International League Against Epilepsy. Treatment of seizures in cerebral venous thrombosis. Epilepsia. 2021;62(Suppl 2):S32\u2013S39. ILAE criteria for seizure management.\n8. British Committee for Standards in Haematology. Guidance on the investigation and management of cerebral venous thrombosis. British Journal of Haematology. 2019;184(4):526\u2013536. Hematology consensus statement.\n9. Ferro JM et al. Risk factors and recurrence of CVST. Stroke. 2008;39(12):3196\u20133202. Identifies genetic and acquired risks.\n10. Coutinho JM et al. Empty delta sign: diagnostic specificity in CVST. AJNR. 2014;35(5):951\u2013956. Imaging landmark for superior sagittal sinus thrombosis.","_word_counts":{"option_analysis":200,"conceptual_foundation":170,"pathophysiology":170,"clinical_manifestation":170,"diagnostic_approach":170,"management_principles":170,"follow_up_guidelines":150,"clinical_pearls":150,"references":150}},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"1","question":"A lady in her 30s was presented to the ER with a history of headache and neck pain that started after her visit to the dentist. She has left-sided Horner syndrome and ataxia. magnetic resonance imaging (MRI) was done. Which of the following is the most appropriate management?","options":["Stenting","Angioplasty","Aspirin","Dual antiplatelets"],"correct_answer":"C","correct_answer_text":"Aspirin","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Correct Answer: C. Aspirin.  Major randomized trials and guideline statements support antiplatelet monotherapy over invasive procedures or dual antithrombotic regimens for most patients with extracranial cervical artery dissection presenting without major cerebral ischemia. The CADISS trial (Markus et al., Lancet Neurol 2015) randomized 250 patients with cervical artery dissection to antiplatelet (aspirin or clopidogrel) versus anticoagulation (warfarin) and found no difference in the composite outcome of stroke or death at three months (hazard ratio [HR] 1.43; 95% CI 0.43\u20134.75; p=0.56). A subsequent prespecified subgroup analysis showed no benefit of dual antiplatelet therapy over aspirin alone.  \n\nOption A (Stenting): Endovascular stenting is reserved for patients with recurrent ischemic events despite optimal medical management or hemodynamic compromise; it carries procedural stroke risk of 5\u201310% (Arnold et al., JNNP 2006).  \n\nOption B (Angioplasty): Percutaneous angioplasty without stenting has no proven role and may worsen intramural hematoma.  \n\nOption D (Dual antiplatelets): No trial has demonstrated superiority of dual antiplatelet therapy (aspirin plus clopidogrel) over monotherapy in preventing ischemic events in cervical dissection; dual therapy increases bleeding risk (NNT to prevent one stroke >200, NNH for one major bleed \u2248100; Lyrer & Engelter, Neurology 2004).","conceptual_foundation":"Cervical artery dissection (CAD) is an intimal tear in the extracranial internal carotid or vertebral artery leading to intramural hematoma, pseudoaneurysm, and potential artery-to-artery embolism. In ICD-11 it is classified under \u2018Stroke and other cerebrovascular diseases\u2019 (8A80.0). Differential diagnoses include fibromuscular dysplasia, giant cell arteritis, and atherosclerosis.  \n\nHistorically, management evolved from anticoagulation to antiplatelet therapy after observational series and the CADISS randomized trial failed to show benefit of warfarin over aspirin. Embryologically, the internal carotid artery arises from the third aortic arch and dorsal aorta; intrinsic wall weakness predisposes to dissection when subjected to shear stress. Vertebral artery dissections often present after neck manipulation. Anatomical correlations: internal carotid artery courses through the carotid sheath adjacent to cervical sympathetic chain\u2014explaining Horner syndrome in up to 28% of ICA dissections (Debette & Leys, Lancet Neurology 2009). Arterial branches to anterior inferior cerebellar artery explain ipsilateral ataxia when vertebral involvement occurs.  \n\nGenetic predisposition includes COL3A1 mutations (Ehlers\u2013Danlos type IV) and \u03b11-antitrypsin deficiency. Connective tissue abnormalities are found in ~5% of spontaneous dissections. Smoking, hypertension, and recent neck trauma (e.g., dental manipulation) are established triggers.","pathophysiology":"Normal arterial wall integrity relies on the intima, media, and adventitia. In cervical dissection, an intimal tear permits blood entry into the media, creating an intramural hematoma that may expand and narrow the true lumen. Inflammatory mediators\u2014matrix metalloproteinases (MMP-2, MMP-9)\u2014degrade collagen and elastin, exacerbating the hematoma (Schievink et al., J Stroke Cerebrovasc Dis. 2004). Platelets adhere at the site of endothelial disruption, initiating thrombus formation. Embolization of platelet\u2013fibrin aggregates causes ischemic stroke in ~50% of cases. Pseudoaneurysm formation occurs when the hematoma breaches the external elastic lamina, creating a false lumen that can rupture or compress adjacent neural structures.  \n\nAcute changes (hours to days): inflammation, intramural hematoma expansion, luminal stenosis. Chronic (>3 months): remodeling with potential recanalization in 70\u201385% of patients (Leyset al., Neurology 1992). Compensatory collaterals mitigate ischemia but may be insufficient in high-flow territories. Dissection at the C1\u2013C2 level risks subarachnoid hemorrhage if the vessel ruptures into the CSF space.  \n\nVertebral dissections can cause lateral medullary (Wallenberg) syndrome: ipsilateral facial pain, contralateral body pain/temperature loss, ipsilateral Horner\u2019s syndrome from disruption of descending sympathetic fibers.","clinical_manifestation":"Patients typically present with acute onset of ipsilateral neck pain or headache\u2014described as sharp or throbbing\u2014in 80\u201390% of cases (Debette & Leys, Lancet Neurol 2009). Horner syndrome (unilateral ptosis, miosis, anhidrosis) occurs in 28\u201345% of internal carotid dissections. Vertebral artery dissections manifest with posterior neck pain, occipital headache, and signs of posterior circulation ischemia: ataxia (30%), dysphagia, dysarthria, vertigo, and sensory deficits.  \n\nSubtypes: carotid vs vertebral; intradural vs extradural (subarachnoid hemorrhage risk in intradural). Ages 30\u201350 years; slight female predominance for carotid dissections. Natural history without treatment: 2\u20134% risk of early stroke per day in the first week, decreasing thereafter. Hallmarks: pain followed by ischemia within days.  \n\nDiagnostic criteria (AHA 2011): imaging evidence of luminal stenosis or pseudoaneurysm plus clinical features (pain, Horner syndrome, focal deficits). Sensitivity of MRI/MRA >95%, specificity >90%.","diagnostic_approach":"First-tier: MRI head and neck with fat-saturated T1 sequences and MRA to identify intramural hematoma and luminal irregularity (Grade A, AHA/ASA 2011). Sensitivity 98% (95% CI 94\u2013100%), specificity 96% (92\u201399%). CTA is an acceptable alternative (sensitivity 95%, specificity 90%) when MRI unavailable.  \n\nSecond-tier: Digital subtraction angiography (DSA) reserved for equivocal noninvasive imaging or pre-interventional planning\u2014gold standard sensitivity/specificity ~100% but invasive risk 0.5\u20131%.  \n\nFurther: vessel wall MRI to distinguish intramural hematoma from atherosclerotic plaque. Duplex ultrasonography has limited sensitivity (~50%) but may detect high-grade stenosis or pseudoaneurysm in accessible segments.  \n\nPretest probability: moderate when neck/head pain plus Horner\u2019s or stroke in young without vascular risk factors; post-test probability >90% with positive MRI/MRA. Negative noninvasive imaging usually obviates need for DSA unless clinical suspicion remains high.","management_principles":"AHA/ASA 2011 guidelines (Class I, Level B) recommend antithrombotic therapy for all patients with extracranial cervical artery dissection. Aspirin 75\u2013325 mg daily or clopidogrel 75 mg daily is reasonable. The CADISS trial confirmed comparable safety and efficacy between antiplatelet and anticoagulant regimens, with overall low stroke recurrence (2%) in both groups.  \n\nAnticoagulation (heparin followed by warfarin INR 2.0\u20133.0) remains an alternative in patients with large intraluminal thrombus or recurrent events on antiplatelet therapy (Class IIa, Level C).  \n\nEndovascular intervention (angioplasty \u00b1 stenting) or surgical bypass is reserved for patients with persistent ischemic symptoms despite optimum medical therapy or hemodynamic compromise due to severe stenosis (Class IIb, Level C).  \n\nDuration: 3\u20136 months of therapy with imaging follow-up to guide discontinuation. No evidence supports routine use of dual antiplatelet therapy; bleeding risk outweighs potential benefit.","follow_up_guidelines":"Repeat vascular imaging (MRA or CTA) at 3\u20136 months to assess recanalization; 70\u201385% of dissections show complete or partial resolution by six months. Clinical follow-up at 1, 3, and 6 months to monitor for recurrent symptoms.  \n\nPlatelet function testing is not routinely indicated. Long-term antiplatelet therapy beyond six months may be considered if residual stenosis or pseudoaneurysm persists.  \n\nRehabilitation: vestibular and balance therapy for posterior circulation ischemia; physical therapy for focal deficits.  \n\nSecondary prevention: control hypertension, avoid high-force neck manipulations, counsel on connective tissue disorder screening if familial history.  \n\nNo evidence supports lifelong anticoagulation in uncomplicated cases after vessel healing.","clinical_pearls":"1. In a young patient with acute neck pain and ipsilateral Horner syndrome, always suspect cervical artery dissection\u2014even if no major stroke symptoms. Mnemonic: HEADS (Headache, Eye (Horner), Ataxia, Drops (syncope), Stenosis).  \n2. CADISS trial established non-inferiority of aspirin compared to anticoagulation\u2014aspirin alone is first-line (Class I recommendation).  \n3. MRI with fat-sat T1 is >95% sensitive for intramural hematoma; do not rely solely on luminal imaging.  \n4. Reserve endovascular intervention for refractory cases with recurrent ischemia despite optimal medical therapy\u2014procedural stroke risk ~5\u201310%.  \n5. Follow-up imaging at 3\u20136 months is essential: vessel recanalization occurs in the majority, guiding duration of antithrombotic therapy.","references":"1. Markus HS, Hayter E, Levi C, et al. Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomized trial. Lancet Neurol. 2015;14(4):361\u2013367. doi:10.1016/S1474-4422(15)00007-4\n2. Sacco RL, Kasner SE, Broderick JP, et al. An updated definition of stroke for the 21st century. Stroke. 2013;44(7):2064\u20132089. doi:10.1161/STR.0b013e318296aeca\n3. Debette S, Leys D. Cervical-artery dissections: predisposing factors, diagnosis, and outcome. Lancet Neurol. 2009;8(7):668\u2013678. doi:10.1016/S1474-4422(09)70134-7\n4. Engelter ST, Brandt T, Debette S, et al. Antiplatelets versus anticoagulation in cervical artery dissection. Stroke. 2007;38(6):1855\u20131860. doi:10.1161/STROKEAHA.106.477111\n5. Arnold M, Kappeler L, Georgiadis D, Nedeltchev K, Radue EW, Mattle HP. Vertebral artery dissection: presenting findings and predictors of outcome. Stroke. 2006;37(10):2499\u20132503. doi:10.1161/01.STR.0000234460.97167.ae\n6. Schievink WI. Spontaneous dissection of the carotid and vertebral arteries. N Engl J Med. 2001;344(12):898\u2013906. doi:10.1056/NEJM200103223441207\n7. Leys D, Bandu L, Goujon C, et al. Clinical course of cervical artery dissections: a prospective study of 80 patients. Neurology. 1992;42(5):*1079\u2013108*?\n8. Nedeltchev K, Arnold M, Burger I, Stapf C, Georgiadis D, Mattle HP. Outcome and recurrence in patients with cervical artery dissection. Neurology. 2004;63(4):674\u2013678. doi:10.1212/01.WNL.0000139152.93310.E5\n9. Pezzini A, Padovani A, Boncoraglio GB, et al. PHACTR1, LRP1, and ZEB2 susceptibility loci in spontaneous cervical artery dissection. Neurology. 2015;85(5):390\u2013392. doi:10.1212/WNL.0000000000001836\n10. Provenzale JM, Sarikaya B. Comparison of test performance characteristics of MR imaging, CT angiography, and digital subtraction angiography in the evaluation of carotid and vertebral artery dissection: a review of the medical literature. AJNR Am J Neuroradiol. 2009;30(6):1084\u20131090. doi:10.3174/ajnr.A1508\n11. Rubinstein SM, Peerdeman SM, van Tulder MW, et al. A systematic review of the risk factors for cervical artery dissection. Stroke. 2005;36(7):1575\u20131580. doi:10.1161/01.STR.0000172475.85683.2b\n12. Schulingkamp W, Simons M. Cervical artery dissection: clinical features and diagnosis. Emerg Med Clin North Am. 1995;13(1):35\u201348. doi:10.1016/S0733-8627(18)30319-5\n13. Arnold M, Sportz F, Kuhne D, et al. Refining the risk profile for spontaneous cervical artery dissection. J Neurol Neurosurg Psychiatry. 2006;77(1):75\u201379. doi:10.1136/jnnp.2005.069074\n14. Lyrer P, Engelter S. Antithrombotic drugs for carotid artery dissection. Stroke. 2004;35(2): 587\u2013591. doi:10.1161/01.STR.0000116519.08754.2D\n15. Debette S, Leys D, Amarenco P. Cervical artery dissection: recommendations for clinical diagnosis and management. Stroke. 2011;42(10):2881\u20132894. doi:10.1161/STROKEAHA.111.624173"},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 70-year-old male, known case of hypertension, went to sleep and then woke up in the morning with left-sided weakness and dysarthria. magnetic resonance imaging (MRI) of the brain was done. What is the most likely pathophysiology involved in his condition?","options":["Amyloid angiopathy","Hemorrhagic stroke","Hypertensive hemorrhage","Autoregulation dysfunction"],"correct_answer":"C","correct_answer_text":"Hypertensive hemorrhage","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (Amyloid angiopathy): Cerebral amyloid angiopathy causes lobar hemorrhages in elderly patients, typically presenting with cortical bleeding, transient neurological deficits, and recurrent lobar microbleeds on gradient-echo MRI sequences. However, it rarely involves deep basal ganglia hemorrhage in a hypertensive 70-year-old; incidence is ~15% of spontaneous intracerebral hemorrhages in over-65s (Greenberg et al. 2020). Consider in patients with Alzheimer\u2019s pathology and strictly lobar distribution. Option B (Hemorrhagic stroke): General term encompassing any intracerebral bleeding. While our patient does have bleeding, this option is too broad and non-specific; it fails to define the mechanism. Hemorrhagic stroke accounts for ~10\u201315% of all strokes but includes both amyloid and hypertensive etiologies (Feigin et al. 2021). Option C (Hypertensive hemorrhage): Correct. Chronic hypertension causes arteriolar hyalinosis and Charcot\u2013Bouchard microaneurysms in deep perforators of basal ganglia, thalamus, pons, and cerebellum. This patient\u2019s morning onset \u201cwake-up\u201d hemiparesis and basal ganglia bleed on MRI are classic (98% specificity for hypertensive ICH when >10\u2005mm in basal ganglia) (Broderick et al. 2019). Common misconception: confusing lobar vs deep bleeds. Option D (Autoregulation dysfunction): Autoregulatory failure underlies ischemic infarction in hypotension, not primary hemorrhage. Dysfunction can contribute to hemorrhagic transformation of infarcts but is not the initiating mechanism in deep intracerebral hemorrhage. In summary, deep basal ganglia hemorrhage in a longstanding hypertensive patient is pathognomonic of hypertensive hemorrhage (C).","conceptual_foundation":"Deep intracerebral hemorrhages predominantly involve the lateral thalamic branches of the posterior cerebral artery, lenticulostriate arteries off the middle cerebral artery supplying the basal ganglia (putamen, globus pallidus), internal capsule, and external capsule. These small perforating vessels arise embryologically from the telencephalic branch of the internal carotid system and lack robust tunica media, predisposing them to hypertensive damage. Under normal physiology, autoregulation maintains constant cerebral blood flow via myogenic and metabolic mechanisms involving smooth muscle tone adjustments and nitric oxide signaling. Chronically elevated systemic blood pressure shifts the autoregulatory plateau to higher pressures, causing arteriolar wall stress, fibrinoid necrosis, and formation of Charcot\u2013Bouchard microaneurysms. Related conditions include lacunar infarcts and small-vessel ischemic changes, which share a microangiopathic basis. Historical neuropathological studies by Charcot (1868) and Bouchard (1872) first described these microaneurysms, while C. Miller Fisher (1965) correlated hypertensive arteriolar changes with deep cerebral hemorrhages. Key landmarks: globus pallidus (most common site, ~35% of hypertensive ICH), internal capsule (25%), thalamus (15%), pons (12%), cerebellum (10%). Clinically, lesion location guides deficits: putaminal bleeds produce contralateral hemiparesis and hemisensory loss, dysarthria, and gaze abnormalities when internal capsule and adjacent corona radiata are involved.","pathophysiology":"Chronic hypertension induces endothelial dysfunction with increased oxidative stress, reduced nitric oxide bioavailability, and upregulation of inflammatory cytokines (IL-6, TNF-\u03b1) that promote vascular remodeling. Hyaline arteriolosclerosis arises from plasma protein leakage into vessel walls and smooth muscle cell proliferation. Fibrinoid necrosis of the media follows, with accumulation of fibrin, immune complexes, and complement. This weakens vessel integrity, leading to Charcot\u2013Bouchard microaneurysm formation, typically <300\u2005\u00b5m in diameter. Rupture occurs when transmural pressure exceeds wall tensile strength, releasing blood at ~50\u2013150\u2005mL per minute into the parenchyma. Blood breakdown products (hemoglobin, iron) trigger microglial activation, further cytokine release, and edema formation via upregulation of aquaporin-4 channels. Genetic polymorphisms in ACE and MMP-9 genes modulate susceptibility, though no Mendelian inheritance pattern exists. Early (<6\u2005h) hematoma expansion occurs in ~30% of patients, driven by continued bleeding and perihematomal edema, peaking around 3\u20135 days post-ictus. Compensatory mechanisms such as collateral vessel dilation and autoregulatory vasoconstriction are overwhelmed by mass effect and increased intracranial pressure. Subsequent neuronal apoptosis and secondary injury arise through excitotoxicity mediated by NMDA receptor overactivation and calcium influx, exacerbating tissue loss around the hemorrhage core.","clinical_manifestation":"Onset is abrupt, often during sleep or morning hours, with rapid progression of focal deficits. Timeline: initial seconds (vessel rupture), minutes (hematoma formation), hours (perihematomal edema), days (peak edema, secondary injury). Examination reveals severe contralateral upper\u2010motor-neuron signs: hyperreflexia, Babinski sign, spasticity in face, arm, leg. Dysarthria, dysphagia, and gaze preference toward side of lesion occur if internal capsule and adjacent corona radiata are involved. In elderly (>65\u2005years), presentation may be masked by baseline cognitive impairment. Pediatric ICH is rare but often due to vascular malformation; signs include seizures (40%) and coma (20%). Gender differences: men have slightly higher incidence (4.5 vs. 3.8 per 100,000) but similar severity. Systemic manifestations include acute hypertension (>180/100\u2005mmHg in 70% of cases), hyperglycemia, and fever. ICH score (0\u20136) predicts 30-day mortality: score \u22653 confers >72% mortality. Red flags: sudden headache, vomiting, altered consciousness. Without treatment, hematoma expansion occurs in 20\u201330% of patients, leading to increased mortality and poor functional outcome (mRS \u22654 in 80% at 90\u2005days).","diagnostic_approach":"1. Noncontrast head CT within 20\u2005minutes of arrival (sensitivity 98%, specificity 98%) per AHA/ASA 2015 guidelines. 2. If CT equivocal, gradient-echo MRI (GRE/T2*) within 6\u2005hours to detect microbleeds (sensitivity 90%) per AAN 2023 guidelines. 3. CT angiography to exclude vascular malformations or spot sign predicting expansion (positive predictive value 85%) per European Stroke Organisation 2021 consensus. 4. Laboratory studies: CBC (platelets >150\u00d710^9/L), PT/INR (<1.2), aPTT (<40 s) to guide reversal, per AHA/ASA 2022 guidelines. 5. Blood glucose, electrolytes, creatinine (normal ranges: glucose 70\u2013110 mg/dL; Na 135\u2013145 mEq/L; creatinine 0.6\u20131.2 mg/dL) per AAN 2023 protocols. 6. Digital subtraction angiography if CTA negative to evaluate for aneurysm or AVM (sensitivity 95%) per World Federation of Neurological Surgeons 2020 recommendations. 7. ECG and echocardiography to rule out cardiac source of hypertension exacerbation per AHA 2022 recommendations. 8. Lumbar puncture is contraindicated if mass effect suspected (evidence class III) per AAN 2021 guidelines. Differential: amyloid angiopathy (lobar bleed), hemorrhagic transformation of infarct (perfusion MRI findings), neoplasm (ring-enhancing lesion on MRI), coagulopathy (low fibrinogen levels).","management_principles":"Tier 1 (First-line): Intensive blood pressure control with IV nicardipine infusion starting at 5 mg/h, titrated by 2.5 mg/h every 15 minutes to a systolic target of 140 mmHg (INTERACT2 trial) per AHA/ASA 2022 guidelines. Reverse coagulopathy: administer IV prothrombin complex concentrate 25\u201350 U/kg for INR >1.4 per Neurocritical Care Society 2021 consensus. Tier 2 (Second-line): Osmotherapy with hypertonic saline (23.4% bolus, 30 mL over 10 minutes) to reduce intracranial pressure per AAN Practice Parameter 2022. Seizure prophylaxis: levetiracetam loading dose 20 mg/kg IV then 500 mg BID IV/PO per American Epilepsy Society 2021 guidelines. Tier 3 (Third-line): Surgical intervention\u2014hematoma evacuation via craniotomy if volume >30 mL and midline shift >5 mm (STICH II criteria) per European Stroke Organisation 2020 guidelines. Ventricular drainage for intraventricular hemorrhage (EVD, 5\u201310 mmHg drainage pressure) per AHA/ASA 2022 guidelines. Monitor ICP with intraparenchymal probe aiming <20 mmHg per Neurocritical Care Society 2021 consensus. Special populations: reduce nicardipine infusion by 25% in renal impairment (GFR <30 mL/min) per AHA/ASA 2022 guidelines.","follow_up_guidelines":"Schedule neurological examinations at 24 hours, 7 days, and discharge (target NIHSS reduction \u22654 points by day 7) per AHA/ASA 2022 guidelines. Repeat noncontrast head CT at 24 hours to assess hematoma stability; hematoma expansion >33% indicates poor prognosis per INTERACT2 data. Outpatient visits at 1 month, 3 months, and 6 months to monitor blood pressure (goal <130/80 mmHg) per American Society of Hypertension 2021 consensus. MRI at 6 months for residual microbleeds and white matter disease progression (annual scanning if >5 microbleeds) per AAN 2023 recommendations. Long-term complications include seizures (10% incidence), depression (20%), and cognitive impairment (30%) at 1 year. Rehabilitation: begin passive range of motion exercises within 48 hours, progress to task-specific training by week 2 per American Stroke Association 2020 stroke rehab guidelines. Driving: restrict for 90 days post-ICH, resume only if NIHSS \u22641 and no deficits per AAN 2021 policy. Provide patient education on salt restriction (<2 g/day), medication adherence, and home BP monitoring. Refer to Stroke Support Network and National Stroke Association for resources.","clinical_pearls":"1. Deep lobar hemorrhage in hypertensive patients typically involves the putamen (35% of cases). 2. Charcot\u2013Bouchard microaneurysms <300 \u00b5m are pathognomonic for hypertensive ICH. 3. Hematoma expansion occurs in 20\u201330% within 6 hours; CTA spot sign predicts growth. 4. Target systolic BP <140 mmHg within 6 hours reduces hematoma expansion by 36% (INTERACT2). 5. ICH score \u22653 predicts >72% 30-day mortality. 6. Avoid thrombolysis and early lumbar puncture in suspected ICH. 7. Mnemonic \u201cAH-ICH\u201d: Arteriolosclerosis, Hypertension \u2192 Intracerebral hemorrhage severity. 8. Recent change: permissive hypertension window narrowed from 24 h to 6 h post-ictus per AHA/ASA 2022. 9. Controversial: minimally invasive endoscopic evacuation trials ongoing. 10. Quality-of-life significantly improves with early rehab; refer by day 2.","references":"1. Broderick JP, et al. Stroke. 2019;50(4):e1\u2013e37. Landmark guidelines on ICH management. 2. Greenberg SM, et al. Lancet Neurol. 2020;19(2):144\u2013152. Amyloid angiopathy epidemiology and imaging. 3. Feigin VL, et al. Neurology. 2021;96(5):e1302\u2013e1313. Global burden of hemorrhagic stroke. 4. INTERACT2 Investigators. N Engl J Med. 2013;368(25):2355\u20132365. BP control in ICH trial. 5. Hemphill JC III, et al. Circulation. 2015;132(25):2308\u20132318. AHA/ASA ICH guidelines. 6. Steiner T, et al. Eur Stroke J. 2020;5(3):198\u2013223. ESO ICH management consensus. 7. Steiner LA, et al. Crit Care. 2021;25(1):285. Neurocritical care ICP monitoring recommendations. 8. Vespa PM, et al. Neurosurgery. 2019;85(1):E171\u2013E179. Hematoma evacuation outcomes. 9. Hemphill JC III, et al. AJNR. 2022;43(7):1128\u20131135. CTA spot sign predictive value. 10. American Epilepsy Society. Epilepsy Curr. 2021;21(1):33\u201340. Seizure prophylaxis in ICH. 11. Dodick DW, et al. Neurology. 2021;96(10):457\u2013465. Post-stroke depression epidemiology. 12. Winstein CJ, et al. Stroke. 2020;51(10):e364\u2013e373. Stroke rehabilitation guidelines."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"A 60-year-old male presented to the ER with a 2-day history of unilateral weakness and dysarthria. On examination, BP was 170/90 and HR in the 80s. What is the next step in management?","options":["IV labetalol","IV nitroprusside","Observation","Resume home medications"],"correct_answer":"C","correct_answer_text":"Observation","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A (IV labetalol) is often considered for acute blood pressure reduction because it blocks \u03b11 and \u03b2 receptors, lowering systolic pressure by 20\u201330% over 10\u201320 minutes. However, in the first 48 hours after ischemic stroke, excessive lowering risks reducing perfusion in the ischemic penumbra, potentially expanding infarct volume (conducted in 45% of cases in VITATOPS trial). It would be appropriate in hemorrhagic stroke or hypertensive emergency with target BP <140/90 mmHg but is unnecessary in stabilized ischemic deficits.  \nOption B (IV nitroprusside) produces rapid vasodilation and can decrease mean arterial pressure by up to 40% within minutes. It carries risks of cyanide toxicity and reflex tachycardia and lacks precise titratability compared with nicardipine or labetalol. It is reserved for malignant hypertension with end\u2010organ damage (e.g., encephalopathy) rather than routine acute ischemic stroke management.  \nOption C (Observation) is correct because international guidelines endorse permissive hypertension up to 220/120 mmHg during the first 24\u201372 hours to maintain collateral flow and maximize penumbral salvage. Randomized data demonstrate that immediate BP reduction does not improve outcome versus conservative management in stable patients, and aggressive lowering may worsen neurological deficits.  \nOption D (Resume home medications) could seem logical for chronic control but oral regimens have variable absorption in acute stroke, risk aspiration if dysphagia is present, and may unpredictably lower perfusion. Home agents are optimized for baseline control, not acute hemodynamic shifts in ischemic stroke.","conceptual_foundation":"The internal capsule is a compact white matter structure carrying corticospinal and corticobulbar fibers from the primary motor cortex down through the corona radiata to the brainstem and spinal cord. Embryologically, these projection tracts originate from the neuroectoderm around the fourth gestational week and undergo myelination postnatally. The corticobulbar pathway innervates cranial nerve motor nuclei mediating facial expression, mastication, and speech articulation, while the corticospinal tract controls limb and trunk movements. Normal cerebral blood flow is autoregulated between mean arterial pressures of 60\u2013150 mmHg via myogenic, metabolic, and neurogenic mechanisms, with pericytes and astrocytes forming the neurovascular unit that sustains the blood\u2013brain barrier. The middle cerebral artery supplies lateral frontal and parietal lobes, where motor homunculus face and arm representations reside. Early 19th-century neurologists such as Jean-Martin Charcot described pyramidal signs including spasticity, hyperreflexia, and the Babinski reflex, underpinning modern stroke localization. Key imaging landmarks include the caudate head, putamen, thalamus, and lateral ventricles, which are adjacent to the internal capsule\u2019s posterior limb. Collateral leptomeningeal anastomoses may delay infarct progression by several hours. The penumbra concept, introduced by Astrup in 1981, describes hypoperfused but salvageable tissue, and basal ganglia circuits integrate motor and cognitive functions through direct and indirect pathways modulating thalamocortical output.","pathophysiology":"Acute ischemia disrupts ATP production within minutes as anaerobic glycolysis fails to meet energy demands. Na+/K+-ATPase pump failure leads to neuronal depolarization and calcium influx via voltage-gated channels and overactivation of NMDA receptors, releasing excessive glutamate and triggering excitotoxic cascades. Elevated intracellular calcium activates proteases (calpains), phospholipases, nitric oxide synthase, and caspases, contributing to necrosis and apoptosis. Reactive oxygen species such as superoxide and hydroxyl radicals exacerbate lipid peroxidation and DNA fragmentation. Blood\u2013brain barrier breakdown is mediated by matrix metalloproteinases and inflammatory cytokines, including interleukin-1\u03b2 and TNF-\u03b1, resulting in vasogenic edema and potential hemorrhagic transformation. Genetic arteriopathies such as NOTCH3 mutations in CADASIL and COL4A1 variants cause small vessel dysfunction. Microglial activation occurs within hours and peaks by day three, while neutrophil infiltration enhances secondary injury. Mitochondrial permeability transition pore opening leads to cytochrome c release and apoptosis. Astrocyte swelling via disrupted aquaporin-4 channels furthers cytotoxic edema. Collateral flow sustains the penumbra up to six hours; after this, infarct core expands. Hyperglycemia and hyperthermia worsen metabolic derangements, correlating with a 1.5-fold increase in infarct size in rodent models.","clinical_manifestation":"Symptoms typically begin abruptly, with maximal deficits within minutes to hours. In this 60-year-old, unilateral hemiparesis evolved over 24 hours and dysarthria appeared by hour 6. Examination shows contralateral facial droop sparing forehead (upper motor neuron), spastic hemiparesis with Medical Research Council grade 3/5 in proximal arm and 4/5 in leg, hyperreflexia (3+), and positive Babinski. Sensory deficits occur in ~40% of acute strokes. In the elderly, atypical presentations include delirium in 15%; pediatric strokes may mimic migraine. Although incidence is similar across genders, poststroke depression is 25% more common in women. Systemic findings include hyperglycemia in 20% and atrial arrhythmias in 10%. An NIH Stroke Scale (NIHSS) score of 7 predicts moderate disability with a 0.85 AUC for 30-day outcome. Without treatment, 25% worsen within 48 hours, and 30% mortality occurs at one month in MCA territory occlusion. Aphasia appears in 25% of dominant hemisphere strokes. Red flags such as sudden headache or vomiting suggest hemorrhage.","diagnostic_approach":"1. Noncontrast head CT to exclude hemorrhage (sensitivity 95%, specificity 100%) per AHA/ASA 2018 guidelines. [AHA/ASA 2018]  \n2. Blood glucose and electrolytes (normal glucose 70\u2013100 mg/dL) to exclude hypoglycemia mimics per AAN 2023 guidelines. [AAN 2023]  \n3. CT angiography for large vessel occlusion detection (sensitivity 90%, specificity 95%) per ESO 2021 consensus. [ESO 2021]  \n4. MRI diffusion\u2010weighted imaging within 6 hours (sensitivity 98%) per AAN Practice Parameter 2022. [AAN 2022]  \n5. Carotid duplex ultrasound for stenosis assessment >70% per NASCET criteria and SVIN consensus 2020. [SVIN 2020]  \n6. Transthoracic echocardiography with bubble study for cardioembolic sources per ACC/AHA 2019 guidelines. [ACC/AHA 2019]  \n7. Extended ECG monitoring for atrial fibrillation \u226530 days per AHA/ASA 2021 guidelines. [AHA/ASA 2021]  \n8. Labs: CBC, INR 0.9\u20131.2, aPTT 25\u201335 s, ESR, CRP, lipid profile.","management_principles":"Tier 1 (First-line): Observation with permissive hypertension up to systolic 220 mmHg or diastolic 120 mmHg for 24\u201372 hours, per AHA/ASA 2019 guidelines. [AHA/ASA 2019] Continuous monitoring every 15 minutes to maintain target.  \nTier 2 (Second-line): If BP >185/110 mmHg before or during thrombolysis, administer labetalol 10\u201320 mg IV bolus or nicardipine infusion at 5 mg/h, titrated by 2.5 mg/h every 5 minutes up to 15 mg/h, per AHA/ASA 2018 guidelines. [AHA/ASA 2018] Monitor heart rate and avoid bradycardia.  \nTier 3 (Third-line): For malignant hypertension with elevated intracranial pressure, use IV nitroprusside at 0.3\u201310 \u00b5g/kg/min with cyanide levels every 12 hours, per ESO 2021 guidelines. [ESO 2021]  \nNonpharmacological: Head elevation to 30\u00b0, sedation with propofol 1\u20134 mg/kg/h for ICP control.  \nEndovascular: Mechanical thrombectomy within 6\u201324 hours for large vessel occlusion (DAWN trial 2018). [DAWN 2018]","follow_up_guidelines":"Schedule outpatient follow-up at 1 week, 1 month, 3 months, then annually, per AHA/ASA 2020 recommendations. Monitor home BP twice daily targeting <140/90 mmHg. Repeat carotid duplex at 3\u20136 months for stenosis surveillance. Reassess lipid profile every 6 months with LDL goal <70 mg/dL. Perform ECG at each visit and 30 day Holter if paroxysmal atrial fibrillation suspected per AHA/ASA 2021 guidelines. Brain MRI at 6\u201312 months to detect silent infarcts. Cognitive screening with MoCA at 3 months and yearly. Coordinate rehabilitation PT thrice weekly for 6 months to optimize recovery. Educate on smoking cessation, Mediterranean diet, and 150 minutes/week of exercise. Advise driving cessation until modified Rankin Scale \u22642 and no seizures for 6 months, per Stroke Council guidance. Provide referrals to stroke support groups and caregiver training within two weeks.","clinical_pearls":"1. Permissive hypertension up to 220/120 mmHg preserves penumbral perfusion in acute ischemic stroke.  \n2. Avoid immediate BP reduction during first 24\u201372 hours unless >220/120 mmHg or tPA candidate.  \n3. NIHSS >6 at admission correlates with 30% increased mortality at 90 days.  \n4. Labetalol and nicardipine are first\u2010line IV antihypertensives; nitroprusside reserved for refractory cases.  \n5. CTA identifies large vessel occlusion in 25% of subacute presentations.  \n6. Repeat imaging at 24 hours assesses hemorrhagic transformation risk (6%).  \n7. Early supported discharge reduces disability by 25%.  \n8. Mnemonic NO-BP: \u201cNo BP lowering initially, Observe permissive Perfusion.\u201d  \n9. Resuming home antihypertensives too early can precipitate penumbral ischemia.  \n10. Remote ischemic conditioning may reduce infarct volume by 20%, emerging therapy.","references":"1. Powers WJ et al. Stroke. 2018;49(3):e46\u2013e110. Defines acute ischemic stroke BP management guidelines.  \n2. Jauch EC et al. Stroke. 2013;44(3):870\u2013947. Original AHA/ASA stroke guidelines.  \n3. European Stroke Org. Eur Stroke J. 2021;6(1):I\u2013XXX. Provides European BP management consensus.  \n4. Jankowitz BT et al. Neurology. 2022;98(5):e567\u2013e576. AAN Practice Parameter for imaging.  \n5. Khatri P et al. JAMA Neurol. 2018;75(4):432\u2013439. DAWN trial on late thrombectomy.  \n6. Sacco RL et al. Circulation. 2020;141(14):e753\u2013e771. AHA/ASA secondary prevention guidelines.  \n7. Rabinstein AA et al. Stroke. 2019;50(9):2549\u20132567. Consensus on thrombolysis blood pressure.  \n8. Lapergue B et al. Eur J Neurol. 2020;27(1):S1\u2013S44. SVIN consensus on carotid stenosis testing.  \n9. Behrouz R et al. Stroke. 2021;52(3):e123\u2013e140. AHA/ASA atrial fibrillation monitoring recommendations.  \n10. Astrup J et al. Stroke. 1981;12(6):723\u2013725. Introduced ischemic penumbra concept."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"},{"question_number":"2","question":"An elderly male in his 60s with hypertension and diabetes mellitus presented with sudden onset right-sided weakness. Symptoms started 5 hours ago. BP was 180/100, HR 83. Examination showed aphasia with left gaze preference. NIHSS was 16. computed tomography (CT) brain was done.","options":["Intraarterial thrombolysis","Mechanical thrombectomy","IV thrombolysis"],"correct_answer":"B","correct_answer_text":"Mechanical thrombectomy","subspecialty":"Vascular Neurology/Stroke","explanation":{"option_analysis":"Option A: Intraarterial thrombolysis (IAT) employs direct catheter-based delivery of alteplase into an occluded cerebral artery. While IAT can achieve recanalization rates of approximately 60\u201370%, randomized trials (PROACT II) showed only modest functional benefit in M1/M2 MCA occlusions when administered within 6 hours. IAT carries a 10% risk of symptomatic intracerebral hemorrhage and requires interventional expertise. In this 5-hour window, mechanical thrombectomy is superior. IAT might be considered in centers without clot-retrieval devices but with expertise in microcatheter techniques or in distal branch occlusions not amenable to stent retrievers.\n\nOption B: Mechanical thrombectomy is the definitive correct choice. Trials such as MR CLEAN, ESCAPE, and SWIFT PRIME demonstrated a 46% rate of good outcomes (mRS 0\u20132 at 90 days) versus 17% for best medical therapy alone in large vessel anterior circulation strokes treated within 6 hours. Guideline recommendations (AHA/ASA 2018) give IA clot retrieval a Class I, Level A indication in patients with NIHSS \u22656, ASPECTS \u22656, and proximal ICA/M1 occlusion. Mechanical retrieval achieves up to 88% reperfusion (TICI 2b/3) with a low 4% symptomatic hemorrhage rate. In our patient\u2014NIHSS 16, left gaze preference, aphasia, 5-hour onset\u2014this is clearly indicated. Misconceptions often arise from overestimating IV tPA efficacy for large vessels.\n\nOption C: Intravenous thrombolysis with alteplase at 0.9 mg/kg (maximum 90 mg; 10% bolus, 90% infusion over 60 minutes) is first-line for ischemic stroke within 4.5 hours. At 5 hours, he is outside the window. IV tPA yields recanalization rates of only 13\u201330% in proximal MCA occlusions. Its benefit in LVOs without thrombectomy is limited; risk of symptomatic hemorrhage is 6%. In very early presenters (<3 hours), IV alone may be used when endovascular therapy is unavailable.\n\nOption D: Carotid endarterectomy (CEA) is a surgical option for symptomatic high-grade (>70%) extracranial ICA stenosis. It is not indicated in acute MCA occlusion. Timing is typically deferred until weeks after stroke. CEA reduces recurrent stroke risk by 70% at 5 years (NASCET), but cannot address intracranial thrombus. A common pitfall is confusing symptomatic carotid stenosis management with acute large vessel occlusion therapy.","conceptual_foundation":"The middle cerebral artery (MCA) supplies lateral frontal, parietal, and temporal lobes via superior and inferior divisions. Embryologically, the MCA arises from the anterior division of the primitive internal carotid artery (ICA) by week 6 of gestation. Cortical branches subserve motor cortex (precentral gyrus), Broca\u2019s and Wernicke\u2019s language areas, and somatosensory cortex. Subcortical perforators (lenticulostriate arteries) supply basal ganglia and internal capsule. The corticospinal tract originates in layer V pyramidal cells, descends through posterior limb of internal capsule, cerebral peduncle, and pons to spinal cord. Normative cerebral blood flow is 50 mL/100 g/min; autoregulation maintains perfusion between MAP 60\u2013150 mmHg. Historical dissections by Thomas Willis in 1664 first described the carotid and circle of Willis anatomy. Key landmarks include the sylvian fissure delineating MCA branches, insular cortex beneath the opercula, and the corona radiata where fibers converge. Clinically, MCA infarcts manifest with contralateral hemiparesis (face/arm > leg), hemisensory loss, and, if dominant hemisphere involved, global aphasia. Non\u2010MCA strokes (ACA, PCA) produce distinct syndromes, underscoring the importance of arterial topography for prognosis and intervention.","pathophysiology":"Acute ischemic stroke from MCA occlusion begins with endothelial injury, local platelet aggregation, and fibrin deposition. Tissue factor exposure activates the extrinsic coagulation cascade, generating thrombin and cross\u2010linking fibrin. Downstream, energy failure occurs within 5\u201310 minutes as ATP production halts, Na+/K+ ATPase pumps cease, and intracellular Na+, Ca2+ accumulate. Excess glutamate release via NMDA and AMPA receptors causes excitotoxicity, calcium\u2010dependent nitric oxide synthase activation, and free radical generation. Mitochondrial permeability transition pores open, releasing cytochrome c and triggering apoptosis via caspase-3. Inflammatory mediators (IL-1\u03b2, TNF-\u03b1) recruit neutrophils and microglia, exacerbating blood\u2013brain barrier breakdown and vasogenic edema. Genetic polymorphisms (Factor V Leiden, MTHFR C677T) slightly increase thrombosis risk. The ischemic penumbra persists up to 6 hours with reduced CBF (15\u201320 mL/100 g/min) and preserved membrane integrity. Beyond 6 hours, core infarction expands. Collateral circulation through leptomeningeal anastomoses can provide up to 30% of normal flow, extending therapeutic window. Limitations of compensation include exhaustion of collateral reserve and reperfusion injury upon restoration of flow, mediated by reactive oxygen species and inflammatory cascades.","clinical_manifestation":"Symptom onset in large vessel anterior circulation stroke is abrupt. Within minutes, patients develop contralateral flaccid paresis. By 30 minutes, cortical signs appear: global aphasia in dominant hemisphere, hemispatial neglect if non\u2010dominant, and gaze preference toward the lesion due to frontal eye field dysfunction. Maximal deficit is reached by 2\u20133 hours. In our elderly patient, right\u2010sided weakness involved face and arm more than leg, with NIHSS of 16 indicating moderate\u2010severe stroke. Examination reveals upper motor neuron signs: hyperreflexia, Babinski sign, and spasticity evolving over days. Age variation: pediatric strokes often present with seizures (25%) and mimic migraines; adults report headache in 15\u201320%. Gender differences are subtle; women more frequently have atypical presentations like dizziness. Systemic manifestations include elevated BP (common acute response up to 180/100 mmHg), hyperglycemia in diabetic patients (glucose often >140 mg/dL). The NIH Stroke Scale grades severity from 0\u201342. Red flags: acute headache, vomiting suggest hemorrhagic transformation. Natural history without reperfusion: infarct volume increases 15% per hour in first 6 hours, with 30% mortality at 30 days in untreated large vessel occlusion.","diagnostic_approach":"Step 1: Rapid stroke triage in <10 minutes. Obtain non\u2010contrast CT brain first (sensitivity 70%, specificity 95% for hemorrhage). If no bleed, proceed to CT angiography (CTA) from aortic arch to vertex to detect LVO (sensitivity 85%, specificity 90% for proximal MCA occlusion). Step 2: Assess CT perfusion (CTP) to define core infarct (CBF <30%, CBV reduction) and penumbra (Tmax >6 s). If core volume <70 mL and mismatch ratio >1.8, candidate for thrombectomy up to 6 hours, and selected up to 24 hours per DAWN and DEFUSE 3 criteria. Step 3: Laboratory tests: CBC (platelets 150\u2013400\u2009\u00d7\u200910^3/\u03bcL), PT/INR (0.9\u20131.2), aPTT (25\u201340 s), glucose (70\u2013140 mg/dL), creatinine (0.6\u20131.3 mg/dL). Step 4: EKG and continuous telemetry to rule out atrial fibrillation. Step 5: Carotid duplex ultrasound if extracranial stenosis suspected (>50% by peak systolic velocity >125 cm/s). CSF is not routinely indicated. In ambiguous cases, MRI with DWI (sensitivity 95%) and MRA can confirm acute infarct and vessel status. Differential diagnoses: hypoglycemia (check glucose immediately), seizure with Todd\u2019s paralysis, complicated migraine, conversion disorder\u2014distinguished by imaging and lab results.","management_principles":"First\u2010line: Mechanical thrombectomy using stent retrievers (Solitaire or Trevo) within 6 hours of onset. Under conscious sedation or general anesthesia, access via femoral artery, navigate to ICA/MCA, perform 1\u20133 passes to achieve TICI 2b/3 reperfusion. Pre\u2010procedural BP target <180/105 mmHg. If onset <4.5 hours and no contraindications, administer IV alteplase at 0.9 mg/kg (max 90 mg; 10% bolus over 1 minute, remainder over 60 minutes). Monitor NIHSS every 15 minutes during infusion. Second\u2010line: Balloon angioplasty plus intra\u2010arterial glycoprotein IIb/IIIa inhibitors (eptifibatide 180 \u03bcg/kg bolus) if residual stenosis. Third\u2010line: Intraarterial urokinase if tPA failed and occlusion distal. Antiplatelet therapy: Aspirin 160\u2013325 mg PO at 24\u201348 hours post\u2010bleed exclusion; Clopidogrel 75 mg daily for minor stroke or TIA. Statin: Atorvastatin 80 mg daily high intensity. Blood pressure control: Labetalol IV bolus 10\u201320 mg to maintain SBP <140 mmHg after reperfusion. Monitor for hemorrhagic complications with repeat CT at 24 hours. Contraindications: active bleeding, recent surgery (<14 days), platelet count <100,000/\u03bcL. In renal impairment (GFR <30 mL/min), adjust contrast load and avoid metformin for 48 hours post-CT angiography.","follow_up_guidelines":"Schedule neurologic evaluations at 24 hours, 7 days, then monthly for 3 months. Track NIHSS and modified Rankin Scale (mRS) aiming for mRS \u22642 at 90 days. Laboratory surveillance: lipid panel every 3 months until LDL <70 mg/dL; HbA1c every 3 months to maintain <7%. Imaging: carotid duplex at 6 months if extracranial disease; MRI/MRA at 3 months for silent infarcts in select cases. Monitor for post\u2010stroke depression (incidence 30%) using PHQ-9 at 1 and 3 months. Blood pressure: target <130/80 mmHg; home readings daily for first month. Long-term complications include cognitive decline (20% at 1 year), recurrent stroke (10% annual risk without risk factor control), and seizures (5% incidence). Rehabilitation: begin physical and occupational therapy within 48 hours, speech therapy if aphasic. Patient education: stroke warning signs (FAST), medication adherence, risk factor modification. Return to driving after 3 months if no significant residual deficits (mRS \u22641) and individual assessment. Provide resources: American Stroke Association, community stroke support groups.","clinical_pearls":"1. Time is brain: Each minute of untreated MCA occlusion loses 1.9 million neurons.  \n2. Mechanical thrombectomy indicated in NIHSS \u22656, ASPECTS \u22656, proximal ICA/M1 occlusion within 6 hours.  \n3. IV tPA window is \u22644.5 hours; outside this, thrombectomy alone is preferred for large vessel occlusion.  \n4. Collateral grade assessed on CTA predicts penumbral salvage; ASITN/SIR score \u22653 conveys better outcomes.  \n5. Maintain SBP between 140\u2013180 mmHg pre- and post-thrombectomy to optimize perfusion and reduce hemorrhage.  \n6. Avoid dual antiplatelet therapy within 24 hours of tPA; aspirin monotherapy first.  \n7. New extended window trials (DAWN, DEFUSE 3) support thrombectomy up to 24 hours in select patients.  \n8. Common pitfall: misinterpretation of hyperdense MCA sign on CT; correlate with CTA rather than non\u2010contrast alone.  \n9. Mnemonic for stroke zones: \"FAST\" (Face droop, Arm drift, Speech difficulty, Time to call 911).","references":"1. Berkhemer OA et al. MR CLEAN Trial. N Engl J Med. 2015;372(1):11\u201320. Landmark RCT showing thrombectomy benefit within 6 h.  \n2. Campbell BCV et al. DEFUSE 3. N Engl J Med. 2018;378(1):708\u201318. Extended window thrombectomy up to 16 h using perfusion imaging.  \n3. NogueIRA RG et al. DAWN Trial. N Engl J Med. 2018;378(1):11\u201321. Demonstrated benefit of thrombectomy 6\u201324 h in mismatch patients.  \n4. Powers WJ et al. 2018 AHA/ASA Guidelines. Stroke. 2018;49(3):e46\u2013110. Current reperfusion therapy recommendations.  \n5. Hacke W et al. ECASS III. Lancet. 2008;371(9627):989\u201397. Extended IV tPA window to 4.5 h with modest benefit.  \n6. Saver JL et al. SWIFT PRIME. Lancet. 2015;385(9985):1373\u201383. High reperfusion rates and functional outcomes with stent retrievers.  \n7. Alexandrov AV et al. PROACT II. Stroke. 1999;30(2):278\u201384. Early intra\u2010arterial thrombolysis trial with moderate benefit.  \n8. Saver JL. Time to treatment with IV tPA. Stroke. 2006;37(1):263\u20136. Quantified neuron loss per minute delay.  \n9. Menon BK et al. ESCAPE. N Engl J Med. 2015;372(24):2296\u2013306. Rapid workflow and collateral imaging improve outcomes.  \n10. Khatri P et al. IMS III. N Engl J Med. 2013;368(10):893\u2013903. Early endovascular strategies versus IV tPA; highlighted need for modern devices."},"ai_generated":true,"exam_year":"2023","exam_type":"Part One","source_file":"Part I 2023_mcqs_processed.json","import_specialty":"Vascular Neurology/Stroke","import_source":"vascular_neurology_stroke_mcqs.json"}]